Search results for "Carcinoma"

showing 10 items of 3529 documents

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice

2012

Background & Aims CYLD is a tumor suppressor gene that is mutated in familial cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. Reduced CYLD expression has been observed in other tumor entities, including hepatocellular carcinoma. In the present study, we analyzed the role of CYLD in liver homeostasis and hepatocarcinogenesis in vivo . Methods Mice with liver-specific deletion of CYLDexon7/8 ( CYLD FF xAlbCre ) were generated. Liver tissues were histologically analyzed and oval cell activation was investigated. Hepatocarcinogenesis was induced by diethylnitrosamine/phenobarbital (DEN/PB). Microarray expression profiling of livers was performed in untreated …

medicine.medical_specialtyTumor suppressor geneBiliary Tract DiseasesIn Vitro TechniquesBiologymedicine.disease_causeDimethylnitrosamineDeubiquitinating Enzyme CYLDMiceRisk FactorsFibrosisInternal medicinemedicineAnimalsHomeostasisGenetic Predisposition to DiseaseHepatologyLiver NeoplasmsExonsTransforming growth factor betamedicine.diseaseFibrosisMice Mutant StrainsDeubiquitinating Enzyme CYLDMice Inbred C57BLGene expression profilingCysteine EndopeptidasesDisease Models AnimalPhenotypeEndocrinologyLiverPhenobarbitalHepatocellular carcinomaCancer researchbiology.proteinCell activationCarcinogenesisGene DeletionJournal of Hepatology
researchProduct

Prediction model of lymph node metastasis in superficial esophageal adenocarcinoma and squamous cell cancer including D2-40 immunostaining

2009

Background It was the aim of our study to establish a model for prediction of lymph node metastases in superficial esophageal cancer. Methods We analyzed the clinical and histopathological data of 50 consecutive patients with pT1-esophageal cancer who underwent oncological resection. Submucosal carcinomas (pT1b) were classified according to sm levels 1–3. D2-40 immunostaining was investigated using the ABC technique. In a first step, we performed univariate analysis (One-way ANOVA: Sigma restricted parameterization; test of SS whole vs. SS predicted) to test the predictive value of the following categorical parameters for lymph node status (positive/negative): sex, histologic tumor type, lo…

medicine.medical_specialtyUnivariate analysisPathologyMultivariate analysisbusiness.industryGeneral MedicineEsophageal cancermedicine.diseaseLymphatic systemmedicine.anatomical_structureOncologyLymphatic vesselCarcinomaMedicineSurgeryRadiologybusinessGrading (tumors)Lymph nodeJournal of Surgical Oncology
researchProduct

Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

2001

Objective  To determine the need to standardize the number and location of lymph nodes to be removed during radical cystectomy in patients with invasive bladder carcinoma. Patients and methods  The pelvic lymph nodes from 447 patients (mean age 62.8 years) who underwent radical cystectomy between 1986 and 1997 were evaluated. The number of lymph nodes was correlated with the depth of invasion of the primary tumour (pT), occurrence of nodal metastases, clinical outcome, the operating surgeons and the pathologists dissecting the nodes. Results  The clinical follow-up was available for 302 patients (mean follow-up 38.7 months). The mean (range) number of lymph nodes removed was 14.7 (1–46). Th…

medicine.medical_specialtyUrinary bladderBladder cancerbusiness.industryUrologymedicine.medical_treatmentmedicine.diseaseSurgeryCystectomyTransitional cell carcinomamedicine.anatomical_structuremedicineCarcinomaLymphadenectomyLymphRadiologybusinessLymph nodeBJU International
researchProduct

Intravesical Treatment of Superficial Urinary Bladder Tumours with Adriamycin

1980

Personal experience resulted in the observation that intravesical Adriamycin (ADM) is effective in some patients with multiple or diffuse papillary bladder tumours. A review of the literature shows that similar results have been obtained elsewhere, especially in Japan and Sweden. The response rate was higher if single doses of at least 50 mg were employed. Intravesical instillations of ADM appear to be valuable also in the treatment of carcinoma in situ and in prophylactic treatment after transurethral resection (TUR) of papillary bladder tumours.

medicine.medical_specialtyUrinary bladderbusiness.industryCarcinoma in situUrologymedicine.diseaseResectionNeck of urinary bladderTransitional cell carcinomaIntravesical treatmentmedicine.anatomical_structureIntravesical instillationmedicinebusinessProphylactic treatment
researchProduct

Development of Bladder Carcinoma Following Portacaval Shunt in Rats

1987

Portacaval anastomosis (PCA) was first introduced by Eck (1877) and was investigated in a number of different animals. Lee et al. (1961; 1974) published a reliable method with low mortality in rats. The occurrence of urolithiasis in rats following portacaval anastomosis happened to be noticed by chance. It was published by Herz et al. (1972a, 1972b, 1973), who defined the portacaval shunt rat as an experimental model. Heine et al. (1979) described dysplastic and neoplastic changes of the bladder mucosa following portacaval anastomosis. His findings were confirmed by Duy et al. (1981); Grun et al. (1982), and Dubuisson et al. (1984). However, Wallace et al. (1984) found papillary hyperplasia…

medicine.medical_specialtyUrinary bladderbusiness.industryPortacaval anastomosisUrologyPortacaval shuntmedicine.diseasemedicine.anatomical_structureBladder NeoplasmmedicineCarcinomaBladder stonesbusinessBladder stoneUpper urinary tract
researchProduct

Follow-up results of embolization therapy for palliation of incurable bladder carcinoma

1985

Embolization therapy of the renal artery (N=10), hypogastric arteries (N=18) and ureter (N=24) was performed in 41 patients with incurable bladder carcinoma for palliation of gross hematuria and severe dysuria. Careful follow-up of the patients until death gave a mean survival time of 12.3 months after embolization; 6 patients are still alive. The results show that embolization therapy is justified for management of bleeding and dysuric complaints. Ureteral occlusion alone has almost no effect on hematuria. Combined embolization procedures yield better results than occlusion of the vessels or the ureter. Ureteral occlusion with a detachable balloon is superior to embolization with tissue ad…

medicine.medical_specialtyUrinary bladderbusiness.industryUrologymedicine.medical_treatmenturologic and male genital diseasesmedicine.diseaseInternal iliac arteryfemale genital diseases and pregnancy complicationsSurgerymedicine.anatomical_structureUretermedicine.arteryOcclusionCarcinomaMedicineDysuriaRadiologyEmbolizationRenal arterymedicine.symptombusinessWorld Journal of Urology
researchProduct

Electrochemical detection and screening of bladder cancer recurrence using direct electrochemical analysis of urine: A non-invasive tool for diagnosis

2018

Although detection of urothelial cell carcinoma (or bladder cancer, BC) can be performed via cytological, molecular and genetic marker tests on urine, cystoscopy, an invasive technique, still remains as the gold methodology in clinical practice. It is presented a non-invasive method for detecting BC recurrence consisting of a direct electrochemical test in urine combining voltammetric data at gold and glassy carbon electrodes. The diagnosis is based on the ratio between characteristic voltammetric features recorded for tryptophan, serotonin and melatonin and other related metabolites. The method was tested by means of a clinical trial with 30 patients diagnosed of bladder cancer and a two c…

medicine.medical_specialtyUrinary systemUrology02 engineering and technologyElectrochemical detectionUrineUrine010402 general chemistry01 natural sciencesUrothelial cell carcinomaMaterials ChemistrymedicineElectrochemistryElectrical and Electronic EngineeringInstrumentationBladder cancermedicine.diagnostic_testbusiness.industryNon invasiveBladder cancerMetals and AlloysCystoscopyNon-invasive diagnostic021001 nanoscience & nanotechnologyCondensed Matter Physicsmedicine.disease0104 chemical sciencesSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsClinical trial0210 nano-technologybusiness
researchProduct

Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides.

2020

Abstract Background Muscle-invasive bladder cancer (MIBC) is the second most common genitourinary malignancy, and is associated with high morbidity and mortality. Recently, molecular subtypes of MIBC have been identified, which have important clinical implications. Objective In the current study, we tried to predict the molecular subtype of MIBC samples from conventional histomorphology alone using deep learning. Design, setting, and participants Two cohorts of patients with MIBC were used: (1) The Cancer Genome Atlas Urothelial Bladder Carcinoma dataset including 407 patients and (2) our own cohort including 16 patients with treatment-naive, primary resected MIBC. This resulted in a total …

medicine.medical_specialtyUrology030232 urology & nephrologyH&E stainDiseaseMalignancy03 medical and health sciences0302 clinical medicineDeep LearningCarcinomamedicineHumansNeoplasm InvasivenessBladder cancerReceiver operating characteristicbusiness.industryDeep learningmedicine.diseaseMolecular Diagnostic TechniquesUrinary Bladder Neoplasms030220 oncology & carcinogenesisHistopathologyArtificial intelligenceRadiologybusinessForecastingEuropean urology
researchProduct

Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis.

2003

Abstract Objective: Pathologists play a pivotal role in the diagnosis and in the report of the pathological features related to prognosis. Methods: To meet these endpoints, the following issues must be accomplished: adequate information about the patient history, proper handling of the specimens, identification of the reliable histopathological techniques necessary to reach the more detailed diagnostic information and evaluate the prognostic variables, and a standardized pathological report. Results: Recent efforts to standardize the histopathological evaluation have generated significant confusion among the urological and pathological communities as well. No consensus has been achieved abo…

medicine.medical_specialtyUrologyBiopsySpecimen HandlingmedicineHumansMedical historyKidney PelvisPhysician's RoleGrading (tumors)Neoplasm StagingBladder cancerPathology Clinicalbusiness.industryUreteral NeoplasmsAnatomical pathologyProfessional PracticePathology Reportmedicine.diseasePrognosisKidney NeoplasmsSurgerySquamous carcinomamedicine.anatomical_structureEpidermoid carcinomaUrinary Bladder NeoplasmsRadiologybusinessRenal pelvisEuropean urology
researchProduct

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell…

1996

Objectives. To evaluate a selected population of 50 consecutive patients with primary T1, G3 bladder transitional cell carcinoma in the absence of carcinoma in situ (Tis) treated with a bladder-sparing approach. Methods. Between January 1983 and December 1992, all patients were treated by transurethral resection (TUR) plus adjuvant intravesical chemotherapy over 1 year. In most cases, doxorubicin, epirubicin, and mitomycin were used alone or in combination. Results. At a mean follow-up period of 52 months (range, 18 to 126), 16 of 50 patients (32%) showed a recurrent superficial tumor. The recurrent lesion was of Stage T1 in 11 (22%) cases, but was a T1, G3 tumor only in 5 cases (10%). In 2…

medicine.medical_specialtyUrologymedicine.medical_treatmentPopulationAntineoplastic AgentsMitomycinsSettore MED/24 - UrologiaCystectomyUrethraCarcinomamedicineHumansBACILLUS CALMETTE-GUERINeducationEpirubicinNeoplasm StagingCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryCarcinoma in situmedicine.diseaseCombined Modality TherapyCANCERSurgeryAdministration Intravesicalmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinSurgical Procedures OperativeNeoplasm Recurrence LocalbusinessFollow-Up StudiesEpirubicinmedicine.drugUrology
researchProduct